AI Tool Developed to Optimize Bowel Cancer Treatment and Reduce Unnecessary Side Effects
Scientists from the Institute of Cancer Research in London and the RCSI University of Medicine and Health Sciences in Dublin have developed an AI tool called PhenMap. This tool is designed to identify colorectal cancer (CRC) patients who are most likely to benefit from the drug bevacizumab, which has recently been approved for NHS use in treating metastatic CRC. The AI analyzes genetic data and other clinical information to score patients based on their likelihood of benefiting from the drug, which is known to cause serious side effects in some patients. The research, published in Scientific Reports, aims to improve treatment outcomes and reduce unnecessary side effects by targeting the drug to patients who will benefit the most. 
